RxDoctor Payments Data

Erin Diamond-Paulsen

Family · Wake Forest, NCNPI 1437673522

Payments from drug & device makers

$1,667in general payments, 2019–2025

Across 64 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$525
  • Lilly USA, LLC$299
  • Bayer$193
  • Amgen$125
  • Abbott$96
  • Exact Sciences$89
  • plus $340 from 12 others

What the payments were for

  • Food & beverage$1,667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,667 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$21,707
Medicare patients
96
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide21$21,570
RybelsusSemaglutide15$19,293
MounjaroTirzepatide17$18,019
FarxigaDapagliflozin Propanediol11$15,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,103
Breo ElliptaFluticasone/Vilanterol13$5,979
Losartan Potassium87$1,416
Levothyroxine Sodium99$1,239
Albuterol Sulfate HfaAlbuterol Sulfate34$1,093
Rosuvastatin Calcium71$861
Atorvastatin Calcium96$759
Bupropion XlBupropion Hcl15$755
Metoprolol Succinate43$748
Amlodipine Besylate126$616
Omeprazole36$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$299$39,59038 claims
Novo NordiskRybelsus$525$19,29315 claims
GSKTrelegy Ellipta, Breo Ellipta$70$19,08229 claims
AstraZenecaFarxiga$15$15,51811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Wake Forest

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →